FAST NEWS: Ascletis Pharma’s Monkeypox Drug Gets IND Approval
The latest: Ascletis Pharma Inc. (1672.HK) announced on Thursday that the China National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for its oral viral polymerase…
FAST NEWS: Ascletis Covid, Monkeypox Virus Inhibitor Gets U.S. Patent
The latest: Ascletis Pharma Inc. (1672.HK) said on Monday the U.S. Patent and Trademark Office (USPTO) has granted it a patent for its oral viral polymerase inhibitor ASC10 and its…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
